Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Avexa
Apricitabine is a new NRTI in development for treatment of drug resistant HIV. Tipranavir is a recently licensed protease inhibitor for treatment of drug resistant HIV. Tipranavir affects the plasma concentration of some other drugs when they are used together with tipranavir. This study will examine whether the pharmacokinetics of apricitabine are changed when it is dosed together with tipranavir compared to apricitabine alone. Also, the pharmacokinetics of tipranavir will be examined at steady state when it is dosed alone and when it is dosed together with apricitabine. Information on the safety and tolerability of the two drugs when dosed together will also be obtained.
Age
18–40
Sex
MALE
Healthy volunteers
Accepted
You may be eligible if
healthy males 18-40 years old
non-smokers
no clinically significant medical history
You may not be if
current or relevant previous medical history of significance
hepatitis B, hepatitis C, or HIV positive
current use of prescription or OTC medications
use of illicit substances or alcohol (\>14 drinks/week)
Clareo Health | Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together
